Me Mingot-Castellano

List of Publications by Year
in descending order

35 papers	569 citations	758635 12 h-index	642321 23 g-index
37 all docs	37 docs citations	37 times ranked	759 citing authors

#	Article	IF	Citations
1	Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. American Journal of Hematology, 2015, 90, E40-3.	2.0	121
2	Use of eltrombopag after romiplostim in primary immune thrombocytopenia. British Journal of Haematology, 2015, 169, 111-116.	1.2	66
3	Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. Platelets, 2019, 30, 743-751.	1.1	45
4	Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10â€year survey. Haemophilia, 2015, 21, 589-597.	1.0	38
5	Molecular and clinical profile of von Willebrand disease in Spain (PCMâ€“EVWâ€“ES): Proposal for a new diagnostic paradigm. Thrombosis and Haemostasis, 2016, 115, 40-50.	1.8	36
6	Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. Haematologica, 2017, 102, 2005-2014.	1.7	35
7	Improvement in clinical outcomes and replacement factor <scp>VIII</scp> use in patients with haemophilia A after factor <scp>VIII</scp> pharmacokineticâ€guided prophylaxis based on Bayesian models with my<scp>PKF</scp>iT^{Â®}. Haemophilia, 2018, 24, e338-e343.	1.0	26
8	Evans syndrome in adults: an observational multicenter study. Blood Advances, 2021, 5, 5468-5478.	2.5	21
9	Hemofilia adquirida: epidemiologÃa, clÃnica, diagnÃ³stico y tratamiento. Medicina ClÃnica, 2017, 148, 314-322.	0.3	20
10	Management of acquired hemophilia A: results from the Spanish registry. Blood Advances, 2021, 5, 3821-3829.	2.5	18
11	Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. onâ€demand therapy with activated factor <scp>VII</scp> in severe haemophilia A patients with inhibitors, in Spain. Haemophilia, 2015, 21, 320-329.	1.0	14
12	Moderate and severe haemophilia in Spain: An epidemiological update. Haemophilia, 2018, 24, e136-e139.	1.0	14
13	Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study. Journal of Clinical Medicine, 2021, 10, 5959.	1.0	9
14	Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain. Case Reports in Hematology, 2017, 2017, 1-8.	0.3	8
15	Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEADâ€US system. Haemophilia, 2021, 27, 479-487.	1.0	8
16	Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study. Blood, 2019, 134, 2361-2361.	0.6	8
17	The factor VIII treatment history of nonâ€severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEADâ€US system. Journal of Thrombosis and Haemostasis, 2021, 19, 2638-2641.	1.9	7
18	Novel Therapies to Address Unmet Needs in ITP. Pharmaceuticals, 2022, 15, 779.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project. PLoS ONE, 2018, 13, e0197876.	1.1	6
20	Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study. Hematology, 2017, 22, 1-9.	0.7	5
21	Global Emerging HEmophilia Panel (GEHEP): A Multinational Collaboration for Advancing Hemophilia Research and Treatment. Transfusion Medicine and Hemotherapy, 2013, 40, 352-355.	0.7	4
22	Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products. Thrombosis Research, 2022, 216, 35-42.	0.8	4
23	Evans' Syndrome in Adults: An Observational Multicentre Study. Blood, 2020, 136, 27-28.	0.6	3
24	Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group. Advances in Hematology, 2019, 2019, 1-11.	0.6	2
25	Adherence to prophylaxis in adult patients with severe haemophilia A. Haemophilia, 2020, 26, 800-808.	1.0	2
26	Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain. European Journal of Haematology, 2020, 105, 94-100.	1.1	2
27	Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts. Revista Espanola De Enfermedades Digestivas, 2020, 112, 778-783.	0.1	2
28	Cytopenias in CAR-T Cell Therapy and Use of Transfusion Resources in Adult Patients with Lymphoproliferative Disorders. Blood, 2021, 138, 3243-3243.	0.6	2
29	Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study. Blood, 2019, 134, 1088-1088.	0.6	1
30	Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up. Blood, 2019, 134, 2370-2370.	0.6	1
31	New treatments for primary immune thrombocytopenia. Blood Coagulation and Fibrinolysis, 2022, 33, S8-S11.	0.5	1
32	Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry. Blood, 2020, 136, 20-21.	0.6	1
33	Hip Replacement Surgery in 14-Year-Old Girl with Factor V Deficiency: Haemostatic Treatment and Thromboprophylaxis. Case Reports in Hematology, 2016, 2016, 1-4.	0.3	0
34	Efficacy of Thrombopoietin Receptor Agonists in Evans Syndrome: An International Multicenter Experience. Blood, 2021, 138, 3155-3155.	0.6	0
35	Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience.. Blood, 0, , .	0.6	0